News
DGX
139.50
+3.90%
5.24
Notable Monday Option Activity: TDG, DGX, DLTR
NASDAQ · 12h ago
Quest Diagnostics, LabCorp climb following FDA testing oversight rule
Quest Diagnostics, LabCorp climb following FDA testing oversight rule. The U.S. FDA issued a final rule aimed at maintaining the safety and effectiveness of laboratory developed tests. Quest is up 5.5%, while LabCorp is up 4.3%. LDTs are commonly used tests that analyze blood, saliva or tissue.
Seeking Alpha · 14h ago
Quest Diagnostics Up Over 5%, on Pace for Largest Percent Increase Since October 2022 -- Data Talk
Quest Diagnostics Incorporated (DGX) is currently at $141.24, up $6.99 or 5.2%. The stock is third best performer in the S&P 500 today. The company is up 6.11% month-to-date and down 18.36% from its all-time high.
Dow Jones · 14h ago
Weekly Report: what happened at DGX last week (0422-0426)?
Weekly Report · 20h ago
Results: Quest Diagnostics Incorporated Beat Earnings Expectations And Analysts Now Have New Forecasts
Quest Diagnostics Incorporated (NYSE:DGX) just released its latest first-quarter results. Revenues beat analyst predictions by 3.5% to hit US$2.4b. Statutory earnings per share came in at US$1.72, beating expectations by 7.5%. The company is expected to grow slower than the industry in the coming years. Quest Diagnostics analysts have not updated their expectations for the company for next year.
Simply Wall St · 3d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Apellis Pharmaceuticals (APLS), Quest Diagnostics (DGX) and Healthcare Services (HCSG)
Analysts have new ratings on Apellis Pharmaceuticals (APLS), Quest Diagnostics (DGX – Research Report) and Healthcare Services (HCSG – Research report) The Street suggests a Strong Buy analyst consensus rating for the Healthcare sector.
TipRanks · 3d ago
Quest Diagnostics: A Hold Rating Amid Solid Earnings and Strategic Caution
TipRanks · 3d ago
Quest Diagnostics Is Maintained at Equal-Weight by Barclays
Dow Jones · 4d ago
Quest Diagnostics Price Target Raised to $144.00/Share From $138.00 by Barclays
Dow Jones · 4d ago
Barclays Maintains Equal-Weight on Quest Diagnostics, Raises Price Target to $144
Benzinga · 4d ago
Labcorp beats quarterly estimates on strong testing demand
Labcorp beats quarterly estimates on strong testing demand. Growing demand for specialty tests boosted sales at its diagnostics business. More people in the U.S. Are catching up on medical procedures and routine check-ups. The company reported first-quarter profit of $3.68 per share.
Reuters · 4d ago
QUEST DIAGNOSTICS INC <DGX.N>: BARCLAYS RAISES TARGET PRICE TO $144 FROM $138
Reuters · 4d ago
Quest Diagnostics Inc Quarterly Report for the Period Ended March 31, 2024
Press release · 5d ago
Peering Into Quest Diagnostics's Recent Short Interest
Quest Diagnostics's short percent of float has fallen 16.83% since its last report. The company has 2.55 million shares sold short, which is 2.62% of all regular shares available for trading. Short interest is the number of shares that have been sold short but have not yet been covered.
Benzinga · 5d ago
Quest Diagnostics Is Maintained at Neutral by Citigroup
Dow Jones · 5d ago
Quest Diagnostics Price Target Raised to $145.00/Share From $135.00 by Citigroup
Dow Jones · 5d ago
Citigroup Maintains Neutral on Quest Diagnostics, Raises Price Target to $145
Benzinga · 5d ago
Quest Diagnostics Is Maintained at Neutral by UBS
Dow Jones · 5d ago
UBS Maintains Neutral on Quest Diagnostics, Raises Price Target to $146
Benzinga · 5d ago
QUEST DIAGNOSTICS INC <DGX.N>: JEFFERIES RAISES TARGET PRICE TO $160 FROM $155
Reuters · 5d ago
More
Webull provides a variety of real-time DGX stock news. You can receive the latest news about Quest Diagnostics Inc through multiple platforms. This information may help you make smarter investment decisions.
About DGX
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through the DIS segment, which provides diagnostic information services to a range of customers within its primary customer channels: physicians, hospitals, and patients and consumers. It provides diagnostic information services for infectious diseases, such as tuberculosis (e.g., T.SPOT.TB and Quantiferon offerings) and tick-borne disease (e.g., Accutix offering). Its comprehensive offerings in drug monitoring and toxicology, in neurology diagnostics, in advanced cardiovascular diagnostic information services (e.g. CARDIO IQ and Cleveland HeartLab offerings through its Cardiometabolic Center of Excellence), and in cancer diagnostics. Its Diagnostic Solutions business consists of its risk assessment services and healthcare information technology businesses. Its risk assessment service, ExamOne, is a provider of risk assessment services for the life insurance industry in North America.